Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 8-K (Current Report)
Date of Report: March 10, 2025
Event: Entry into a Fifth Amendment to its term loan and senior revolving credit facility to address non-compliance with financial covenants and establish a refinancing timeline.
Key Financial Metrics and Debt Status
- Covenant Waiver: Lenders waived non-compliance with the consolidated net leverage ratio covenant as of December 31, 2024.
- Revolving Credit Facility: Commitment capped at the amount outstanding as of March 10, 2025.
- Interest Rate: Increased to SOFR plus 400 basis points.
- Amortization: Revised to require monthly proportionate payments instead of quarterly.
- Transaction Fees: $0.1 million paid to lenders.
- Liquidity Requirement: Must maintain minimum liquidity of $3.5 million (unrestricted cash plus undrawn revolver capacity).
- Financial Performance: The filing does not provide specific revenue, profit, or cash flow figures for the period.
Material Changes and Refinancing Milestones
The Fifth Amendment establishes a strict timeline for refinancing the debt underlying the Credit Agreement. Failure to meet these milestones may impact the waiver of financial covenants for the quarter ended March 31, 2025.
- March 14, 2025: Engagement of a financial advisor acceptable to the administrative agent.
- April 30, 2025: Delivery of an executed bona fide indication of interest from potential lenders.
- May 23, 2025: Delivery of a term sheet or commitment letter for the refinancing.
- June 13, 2025: Delivery of sources and uses statement and evidence of satisfied closing conditions.
- June 30, 2025: Closing of the refinancing.
Outlook, Risks, and Management Commentary
Going Concern Uncertainty: The Company explicitly states there is "substantial doubt" about its ability to continue as a going concern. While current cash and operations are expected to fund activities through the refinancing process, the Company will be unable to pay debt obligations or fund operations beyond June 30, 2025, unless it secures adequate capital or extends the repayment date.
Risks: The ability to access alternative sources of capital is uncertain. Forward-looking statements regarding the refinancing and operational funding involve significant risks and assumptions outside the Company's control.
Investor Verification Checklist
- Verify the status of the financial advisor engagement by March 14, 2025.
- Monitor the receipt of indications of interest and term sheets by late April and May 2025.
- Confirm the Company maintains the required $3.5 million minimum liquidity threshold.
- Assess the likelihood of closing the refinancing by the June 30, 2025 deadline to avoid default.
- Review the full text of the Fifth Amendment (Exhibit 10.1) for specific default triggers and conditions.